Dyadic International Inc. (NASDAQ:DYAI) Short Interest Up 754.7% in May

Dyadic International Inc. (NASDAQ:DYAI) was the target of a significant growth in short interest in May. As of May 29th, there was short interest totaling 622,465 shares, a growth of 754.7% from the May 14th total of 72,829 shares. Approximately 2.2% of the shares of the stock are sold short. Based on an average daily trading volume, of 1,064,040 shares, the days-to-cover ratio is presently 0.6 days.

Dyadic International Trading Up 7.0%

NASDAQ DYAI traded up $0.05 on Wednesday, reaching $0.72. 80,090 shares of the company were exchanged, compared to its average volume of 159,824. The business’s fifty day moving average price is $0.79 and its 200 day moving average price is $0.84. The stock has a market capitalization of $26.35 million, a P/E ratio of -3.14 and a beta of 1.17. The company has a current ratio of 2.42, a quick ratio of 2.42 and a debt-to-equity ratio of 4.08. Dyadic International has a fifty-two week low of $0.65 and a fifty-two week high of $1.35.

Dyadic International (NASDAQ:DYAI) last posted its earnings results on Wednesday, May 13th. The biotechnology company reported ($0.05) EPS for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.01). Dyadic International had a negative net margin of 192.40% and a negative return on equity of 1,005.45%. The business had revenue of $1.11 million during the quarter, compared to analysts’ expectations of $0.90 million. Analysts forecast that Dyadic International will post 0.13 earnings per share for the current year.

Institutional Investors Weigh In On Dyadic International

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Bank of America Corp DE raised its position in Dyadic International by 16,146.7% in the fourth quarter. Bank of America Corp DE now owns 27,132 shares of the biotechnology company’s stock valued at $47,000 after purchasing an additional 26,965 shares during the period. Marathon Capital Management purchased a new stake in shares of Dyadic International in the 3rd quarter valued at $41,000. Geode Capital Management LLC raised its holdings in shares of Dyadic International by 13.7% in the 4th quarter. Geode Capital Management LLC now owns 301,673 shares of the biotechnology company’s stock valued at $284,000 after buying an additional 36,266 shares during the period. Truist Financial Corp raised its holdings in shares of Dyadic International by 30.5% in the 3rd quarter. Truist Financial Corp now owns 326,200 shares of the biotechnology company’s stock valued at $385,000 after buying an additional 76,200 shares during the period. Finally, Landscape Capital Management L.L.C. purchased a new stake in shares of Dyadic International in the 3rd quarter valued at $190,000. Hedge funds and other institutional investors own 27.95% of the company’s stock.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Dyadic International in a research note on Friday, March 27th. Two equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $3.00.

Dyadic International Company Profile

Dyadic International, Inc is a biotechnology company headquartered in Jupiter, Florida, that specializes in developing and commercializing its proprietary C1 fungal-based expression platform. The company’s core business revolves around enabling efficient, scalable production of proteins and enzymes for a wide range of applications, including biopharmaceuticals, industrial enzymes, agricultural bioactives and biofuels. By leveraging its C1 system, Dyadic seeks to offer clients cost-effective, high-yield manufacturing processes that can accelerate development timelines and reduce overall production costs.

The Dyadic C1 platform is designed to produce complex proteins five to ten times faster than traditional cell culture technologies, such as CHO cells or yeast.